TONIX PHARMACEUTICALS HOLDING CORP. APIC, Share-based Payment Arrangement, Restricted Stock Unit, Increase for Cost Recognition
TONIX PHARMACEUTICALS HOLDING CORP. (TNXP) reported APIC, Share-based Payment Arrangement, Restricted Stock Unit, Increase for Cost Recognition of $2.26 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-10.
Financial Statements › Shareholders' Equity › Adjustments to Additional Paid in Capital
us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition · last filed 2026-08-10
- TONIX PHARMACEUTICALS HOLDING CORP. apic, share-based payment arrangement, restricted stock unit, increase for cost recognition for the quarter ending 2026-06-30 was $2.26M, a 58.54% increase year-over-year.
- TONIX PHARMACEUTICALS HOLDING CORP. apic, share-based payment arrangement, restricted stock unit, increase for cost recognition for the quarter ending 2026-03-31 was $1.97M, a 123.36% increase year-over-year.
- TONIX PHARMACEUTICALS HOLDING CORP. apic, share-based payment arrangement, restricted stock unit, increase for cost recognition for the quarter ending 2025-09-30 was $1.92M, a 85.26% increase year-over-year.
- TONIX PHARMACEUTICALS HOLDING CORP. apic, share-based payment arrangement, restricted stock unit, increase for cost recognition for the quarter ending 2025-06-30 was $1.42M, a 23.31% increase year-over-year.
- TONIX PHARMACEUTICALS HOLDING CORP. apic, share-based payment arrangement, restricted stock unit, increase for cost recognition for fiscal 2025 was $6.02M, a 25.93% increase from fiscal 2024.
- TONIX PHARMACEUTICALS HOLDING CORP. apic, share-based payment arrangement, restricted stock unit, increase for cost recognition for fiscal 2024 was $4.78M, a 48.49% decline from fiscal 2023.
- TONIX PHARMACEUTICALS HOLDING CORP. apic, share-based payment arrangement, restricted stock unit, increase for cost recognition for fiscal 2023 was $9.28M, a 15.02% decline from fiscal 2022.
- TONIX PHARMACEUTICALS HOLDING CORP. apic, share-based payment arrangement, restricted stock unit, increase for cost recognition for fiscal 2022 was $10.91M, a 38.17% increase from fiscal 2021.
| Period end | APIC, Share-based Payment Arrangement, Restricted Stock Unit, Increase for Cost Recognition 3 month | APIC, Share-based Payment Arrangement, Restricted Stock Unit, Increase for Cost Recognition 6 month | APIC, Share-based Payment Arrangement, Restricted Stock Unit, Increase for Cost Recognition 7 month | APIC, Share-based Payment Arrangement, Restricted Stock Unit, Increase for Cost Recognition 9 month | APIC, Share-based Payment Arrangement, Restricted Stock Unit, Increase for Cost Recognition 12 month | APIC, Share-based Payment Arrangement, Restricted Stock Unit, Increase for Cost Recognition 12 month as first filed |
|---|---|---|---|---|---|---|
| 2026-06-30 | $2.26M 10-Q · filed 2026-08-10 | $4.23M derived: sum of 2 quarters · filed 2026-08-10 | ||||
| 2026-03-31 | $1.97M 10-Q · filed 2026-08-10 | |||||
| 2025-12-31 | $6.02M 10-K · filed 2026-03-12 | |||||
| 2025-09-30 | $1.92M 10-Q · filed 2025-11-10 | $3.35M derived: sum of 2 quarters · filed 2026-08-10 | $4.23M derived: sum of 3 quarters · filed 2026-08-10 | |||
| 2025-06-30 | $1.42M 10-Q · filed 2026-08-10 | $2.31M derived: sum of 2 quarters · filed 2026-08-10 | ||||
| 2025-03-31 | $882.00K 10-Q · filed 2026-08-10 | |||||
| 2024-12-31 | $4.78M 10-K · filed 2026-03-12 | |||||
| 2024-09-30 | $1.04M 10-Q · filed 2025-11-10 | $2.19M derived: sum of 2 quarters · filed 2025-11-10 | $3.88M derived: sum of 3 quarters · filed 2025-11-10 | |||
| 2024-06-30 | $1.15M 10-Q · filed 2025-11-10 | $2.85M derived: sum of 2 quarters · filed 2025-11-10 | ||||
| 2024-03-31 | $1.69M 10-Q · filed 2025-11-10 | |||||
| 2023-12-31 | $9.28M 10-K · filed 2025-03-18 | |||||
| 2023-09-30 | $2.08M 10-Q · filed 2024-11-12 | $4.44M derived: sum of 2 quarters · filed 2024-11-12 | $7.24M derived: sum of 3 quarters · filed 2024-11-12 | |||
| 2023-06-30 | $2.36M 10-Q · filed 2024-11-12 | $5.16M derived: sum of 2 quarters · filed 2024-11-12 | ||||
| 2023-03-31 | $2.79M 10-Q · filed 2024-11-12 | |||||
| 2022-12-31 | $10.91M 10-K · filed 2024-04-01 | |||||
| 2022-09-30 | $2.77M 10-Q · filed 2023-11-09 | $5.58M derived: sum of 2 quarters · filed 2023-11-09 | $8.20M derived: sum of 3 quarters · filed 2023-11-09 | |||
| 2022-06-30 | $2.81M 10-Q · filed 2023-11-09 | $5.43M derived: sum of 2 quarters · filed 2023-11-09 | ||||
| 2022-03-31 | $2.62M 10-Q · filed 2023-11-09 | |||||
| 2021-12-31 | $7.90M 10-K · filed 2023-03-13 | |||||
| 2021-09-30 | $2.30M 10-Q · filed 2022-11-07 | $4.39M derived: sum of 2 quarters · filed 2022-11-07 | $5.60M derived: sum of 3 quarters · filed 2022-11-07 | |||
| 2021-06-30 | $2.09M 10-Q · filed 2022-11-07 | $3.30M derived: sum of 2 quarters · filed 2022-11-07 | ||||
| 2021-03-31 | $1.21M 10-Q · filed 2022-11-07 | |||||
| 2020-12-31 | $2.88M 10-K · filed 2022-03-14 | |||||
| 2020-09-30 | $912.00K 10-Q · filed 2021-11-08 | $1.65M derived: sum of 2 quarters · filed 2021-11-08 | $2.00M derived: sum of 3 quarters · filed 2021-11-08 | |||
| 2020-06-30 | $733.00K 10-Q · filed 2021-11-08 | $1.09M derived: sum of 2 quarters · filed 2021-11-08 | ||||
| 2020-03-31 | $360.00K 10-Q · filed 2021-11-08 | |||||
| 2019-12-31 | $1.46M 10-K · filed 2021-03-15 | |||||
| 2019-09-30 | $362.00K 10-Q · filed 2020-11-09 | $793.00K derived: sum of 2 quarters · filed 2020-11-09 | $1.10M derived: sum of 3 quarters · filed 2020-11-09 | $1.47M derived: sum of 4 quarters · filed 2020-11-09 | ||
| 2019-06-30 | $431.00K 10-Q · filed 2020-11-09 | $736.00K derived: sum of 2 quarters · filed 2020-11-09 | $1.10M derived: sum of 3 quarters · filed 2020-11-09 | $1.55M derived: sum of 4 quarters · filed 2020-11-09 | ||
| 2019-03-31 | $305.00K 10-Q · filed 2020-11-09 | $673.00K derived: sum of 2 quarters · filed 2020-11-09 | $1.12M derived: sum of 3 quarters · filed 2020-11-09 | $1.53M derived: sum of 4 quarters · filed 2020-11-09 | ||
| 2018-12-31 | $368.00K derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-24 | $819.00K derived: sum of 2 quarters · filed 2020-03-24 | $1.23M derived: sum of 3 quarters · filed 2020-03-24 | $1.63M 10-K · filed 2020-03-24 | ||
| 2018-09-30 | $451.00K 10-Q · filed 2019-11-08 | $860.00K derived: sum of 2 quarters · filed 2019-11-08 | $1.26M 10-Q · filed 2018-11-09 | $1.57M derived: sum of 4 quarters · filed 2019-11-08 | ||
| 2018-06-30 | $409.00K 10-Q · filed 2019-11-08 | $808.00K 10-Q · filed 2018-08-13 | $1.12M derived: sum of 3 quarters · filed 2019-11-08 | $1.55M derived: sum of 4 quarters · filed 2019-11-08 | ||
| 2018-03-31 | $399.00K 10-Q · filed 2019-11-08 | $712.00K derived: sum of 2 quarters · filed 2019-11-08 | $1.15M derived: sum of 3 quarters · filed 2019-11-08 | $1.62M derived: sum of 4 quarters · filed 2019-11-08 | ||
| 2017-12-31 | $313.00K derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-18 | $746.00K derived: sum of 2 quarters · filed 2019-03-18 | $1.22M derived: sum of 3 quarters · filed 2019-03-18 | $1.79M 10-K · filed 2019-03-18 | ||
| 2017-09-30 | $433.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-06 | $910.00K derived: sum of 2 quarters · filed 2017-11-06 | $1.48M 10-Q · filed 2017-11-06 | $2.38M derived: sum of 4 quarters · filed 2018-03-09 | ||
| 2017-06-30 | $477.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-11 | $1.04M 10-Q · filed 2017-08-11 | $1.94M derived: sum of 3 quarters · filed 2018-03-09 | $2.69M derived: sum of 4 quarters · filed 2018-03-09 | ||
| 2017-03-31 | $567.00K 10-Q · filed 2017-05-12 | $1.47M derived: sum of 2 quarters · filed 2018-03-09 | $2.21M derived: sum of 3 quarters · filed 2018-03-09 | $2.94M derived: sum of 4 quarters · filed 2018-03-09 | ||
| 2016-12-31 | $899.00K derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-09 | $1.64M derived: sum of 2 quarters · filed 2018-03-09 | $2.37M derived: sum of 3 quarters · filed 2018-03-09 | $3.27M 10-K · filed 2018-03-09 | ||
| 2016-09-30 | $744.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2016-11-10 | $1.47M derived: sum of 2 quarters · filed 2016-11-10 | $2.37M 10-Q · filed 2016-11-10 | $3.37M derived: sum of 4 quarters · filed 2017-04-13 | ||
| 2016-06-30 | $727.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2016-08-05 | $1.62M 10-Q · filed 2016-08-05 | $2.63M derived: sum of 3 quarters · filed 2017-04-13 | $3.49M derived: sum of 4 quarters · filed 2017-04-13 | ||
| 2016-03-31 | $896.00K 10-Q · filed 2016-05-06 | $1.90M derived: sum of 2 quarters · filed 2017-04-13 | $2.76M derived: sum of 3 quarters · filed 2017-04-13 | $3.94M derived: sum of 4 quarters · filed 2017-04-13 | ||
| 2015-12-31 | $1.00M derived: 10-K 12 month − 10-Q 9 month · filed 2017-04-13 | $1.87M derived: sum of 2 quarters · filed 2017-04-13 | $3.04M derived: sum of 3 quarters · filed 2017-04-13 | $4.39M 10-K · filed 2017-04-13 | ||
| 2015-09-30 | $862.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2015-11-06 | $2.04M derived: sum of 2 quarters · filed 2015-11-06 | $3.38M 10-Q · filed 2015-11-06 | $4.35M derived: sum of 4 quarters · filed 2016-03-03 | ||
| 2015-06-30 | $1.17M derived: 10-Q 6 month − 10-Q 3 month · filed 2015-08-07 | $2.52M 10-Q · filed 2015-08-07 | $3.49M derived: sum of 3 quarters · filed 2016-03-03 | $4.37M derived: sum of 4 quarters · filed 2016-03-03 | ||
| 2015-03-31 | $1.35M 10-Q · filed 2015-05-08 | $2.31M derived: sum of 2 quarters · filed 2016-03-03 | $3.20M derived: sum of 3 quarters · filed 2016-03-03 | $3.85M derived: sum of 4 quarters · filed 2016-03-03 | ||
| 2014-12-31 | $965.00K derived: 10-K 12 month − 10-Q 9 month · filed 2016-03-03 | $1.85M derived: sum of 2 quarters · filed 2016-03-03 | $2.50M derived: sum of 3 quarters · filed 2016-03-03 | $3.05M 10-K · filed 2016-03-03 | $3.09M 10-K · filed 2015-02-27 | |
| 2014-09-30 | $884.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2014-11-07 | $1.53M derived: sum of 2 quarters · filed 2014-11-07 | $2.09M 10-Q · filed 2014-11-07 | $2.53M derived: sum of 4 quarters · filed 2016-03-03 | ||
| 2014-06-30 | $651.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2014-08-08 | $1.20M 10-Q · filed 2014-08-08 | $1.65M derived: sum of 3 quarters · filed 2016-03-03 | $2.09M derived: sum of 4 quarters · filed 2016-03-03 | ||
| 2014-03-31 | $553.00K 10-Q · filed 2014-05-13 | $994.53K derived: sum of 2 quarters · filed 2016-03-03 | $1.44M derived: sum of 3 quarters · filed 2016-03-03 | $1.88M derived: sum of 4 quarters · filed 2016-03-03 | ||
| 2013-12-31 | $441.53K derived: 10-K 12 month − 10-Q 9 month · filed 2016-03-03 | $883.11K derived: sum of 2 quarters · filed 2016-03-03 | $1.32M derived: sum of 3 quarters · filed 2016-03-03 | $1.72M 10-K · filed 2016-03-03 | ||
| 2013-09-30 | $441.57K derived: 10-Q 9 month − 10-Q 6 month · filed 2013-11-13 | $883.14K derived: sum of 2 quarters · filed 2013-11-13 | $1.28M 10-Q · filed 2013-11-13 | |||
| 2013-06-30 | $441.57K derived: 10-Q 6 month − 10-Q 3 month · filed 2013-08-14 | $833.89K 10-Q · filed 2013-08-14 | ||||
| 2013-03-31 | $392.32K 10-Q · filed 2013-05-07 | |||||
| 2012-12-31 | $865.00K 10-K · filed 2014-03-28 | $865.16K 10-K · filed 2013-03-11 | ||||
| 2008-12-31 | $72.00K 10-K · filed 2014-03-28 | $72.56K 10-K · filed 2012-03-30 | ||||
| 2007-12-31 | $24.19K 10-K/A · filed 2013-11-22 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Minerva Neurosciences, Inc. (NERV) | United States | $0.165B | -0.66 |
| ADC Therapeutics SA (ADCT) | $0.163B | -1.39 | |
| LIFECORE BIOMEDICAL, INC. DE (LFCR) | United States | $0.163B | -8.50 |
| Organogenesis Holdings Inc. (ORGO) | United States | $0.182B | -3.70 |
| AN2 Therapeutics, Inc. (ANTX) | United States | $0.185B | -4.84 |
| Annexon, Inc. (ANNX) | United States | $0.147B | -4.22 |
| PepGen Inc. (PEPG) | United States | $0.186B | -1.73 |
| Corbus Pharmaceuticals Holdings, Inc. (CRBP) | United States | $0.144B | -1.72 |
| ALX ONCOLOGY HOLDINGS INC (ALXO) | United States | $0.187B | -3.52 |
| Fortress Biotech, Inc. (FBIO) | United States | $0.188B | 0.91 |